DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative) - USD ($) |
1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 23, 2026 |
Dec. 31, 2025 |
Jul. 31, 2025 |
Jun. 30, 2026 |
May 31, 2026 |
Apr. 30, 2026 |
Jan. 31, 2026 |
Dec. 31, 2025 |
Aug. 31, 2025 |
Jun. 30, 2026 |
Mar. 31, 2026 |
Jun. 30, 2025 |
Mar. 31, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
Dec. 31, 2025 |
Dec. 31, 2024 |
May 31, 2022 |
Jan. 31, 2022 |
Jun. 30, 2020 |
|
| Debt instrument face amount | $ 54,100 | $ 54,100 | $ 54,100 | |||||||||||||||||
| Common stock, par value | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | ||||||||||||||
| Maximum commitment amount | $ 847,470 | $ 70,198 | ||||||||||||||||||
| Shares of common stock | 500,000 | 2,250,000 | 11,877,507 | 137,987 | 300,000 | 1,600,446 | ||||||||||||||
| Sale of common stock | 6,630 | $ 6,630 | ||||||||||||||||||
| Debt conversion amount | $ 150,000 | |||||||||||||||||||
| Net income loss | 341,011 | $ (2,239,276) | $ 210,449 | (364,264) | (1,898,265) | (153,815) | ||||||||||||||
| Net loss | 388,147 | 277,856 | (1,805,629) | (20,860) | 249,300,000 | |||||||||||||||
| Deferred taxes | $ 111,600,000 | |||||||||||||||||||
| Working capital deficit | $ (16,400,000) | (16,400,000) | (16,400,000) | |||||||||||||||||
| Cash flows from operations | 434,440 | 293,106 | ||||||||||||||||||
| Proceeds from Convertible Debt | 500,000 | |||||||||||||||||||
| Mast Hill [Member] | ||||||||||||||||||||
| Proceeds from Convertible Debt | 500,000 | |||||||||||||||||||
| Common Stock [Member] | ||||||||||||||||||||
| Maximum commitment amount | 118,775 | 10,028 | ||||||||||||||||||
| Conversion fee, shares | 2,991,270 | |||||||||||||||||||
| Net income loss | ||||||||||||||||||||
| Securities Purchase Agreements [Member] | ||||||||||||||||||||
| Debt instrument face amount | $ 178,410 | $ 600,000 | $ 398,333 | $ 700,000 | ||||||||||||||||
| Common stock, par value | $ 0.01 | |||||||||||||||||||
| Securities Purchase Agreements [Member] | Common Stock [Member] | ||||||||||||||||||||
| Debt instrument face amount | $ 847,000 | 847,000 | 847,000 | |||||||||||||||||
| Conversion fee, shares | 11,900,000 | |||||||||||||||||||
| Equity Purchase Agreement [Member] | ||||||||||||||||||||
| Maximum commitment amount | $ 25,000,000 | |||||||||||||||||||
| Shares of common stock | 138,000 | |||||||||||||||||||
| Cash proceeds | $ 6,600 | |||||||||||||||||||
| Sale of common stock | $ 1,500 | |||||||||||||||||||
| Independent Contractor Agreement [Member] | ||||||||||||||||||||
| Market capitalization | $ 100,000,000 | $ 100,000,000 | $ 100,000,000 | |||||||||||||||||
| Stockholders equity other | $ 45,000,000 | |||||||||||||||||||
| JH Darbie Placement Agreement [Member] | Accredited Investors [Member] | ||||||||||||||||||||
| Debt conversion amount | $ 2,200,000 | |||||||||||||||||||
| Debt conversion, description | JH Darbie had the right to sell/convert a minimum of 10 Units and a maximum of 200 Units on a best-efforts basis. Two of the investors did not participate in PPM-3 and their 7 units for a total of approximately $0.2 million were converted into short term loan to the Company, of which one investor was paid off during the six months ended June 30, 2026. For more information on the PPM-3 Financing, refer to Note 8 of these Notes to the Condensed Consolidated Financial Statements. | |||||||||||||||||||
| Since Inception Date [Member] | ||||||||||||||||||||
| Net income loss | $ 38,000,000.0 | |||||||||||||||||||
| Point R merger agreement [Member] | ||||||||||||||||||||
| Net loss | 1,900,000 | |||||||||||||||||||
| Working capital deficit | $ 2,600,000 | $ 2,600,000 | $ 2,600,000 | |||||||||||||||||
| GMP Biotechnology Limited [Member] | ||||||||||||||||||||
| Development costs | $ 2,300,000,000 | |||||||||||||||||||
| Golden Mountain Partners [Member] | Securities Purchase Agreement and Purchase Agreement [Member] | ||||||||||||||||||||
| Debt instrument face amount | $ 4,500,000 | $ 4,500,000 | ||||||||||||||||||
| GMP Biotechnology Limited [Member] | ||||||||||||||||||||
| Ownership interest | 45.00% | 45.00% | 45.00% | 45.00% | 45.00% | 45.00% | ||||||||||||||
| Development costs | $ 2,300,000,000 | |||||||||||||||||||
| Increase in fair value ownership | $ 365,400,000 | |||||||||||||||||||
| Dragon Overseas Capital Limited [Member] | ||||||||||||||||||||
| Ownership interest | 55.00% | 55.00% | 55.00% | |||||||||||||||||
| JV [Member] | ||||||||||||||||||||
| Ownership interest | 45.00% | 45.00% | 45.00% | |||||||||||||||||
| JV [Member] | May 2022 Note and July 2025 Note [Member] | ||||||||||||||||||||
| Ownership interest | 45.00% | |||||||||||||||||||
| JV [Member] | May 2022 Note [Member] | ||||||||||||||||||||
| Ownership interest | 45.00% | |||||||||||||||||||
| X | ||||||||||
- Definition Market capitalization No definition available.
|
| X | ||||||||||
- Definition Working capital deficit. No definition available.
|
| X | ||||||||||
- Definition Face amount or stated value per share of common stock. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Description of conversion of original debt instrument in noncash or part noncash transaction. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Face (par) amount of debt instrument at time of issuance. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of capitalized development cost incurred during period and excluded from amortization for oil- and gas-producing activities accounted for under full cost method. Excludes acquisition and exploration costs and capitalized interest. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of unrealized gain (loss) related to the fair value of interest rate derivatives designated as fair value hedging instruments, as offset by the gain (loss) on the hedged item to the extent that the fair value hedge is determined to be effective. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The cash inflow from the additional capital contribution to the entity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of new stock issued during the period. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The gross value of stock issued during the period upon the conversion of convertible securities. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|